Abstract: Endometrial carcinoma is one of the three major malignant tumors in gynecology. The standard treatment is surgery with/without radiotherapy and chemotherapy; for those who desire to retain their fertility can be treated conservatively after consultation and accomplish the operation after childbirth. In 1983, Bockman proposed clinical classification of endometrial cancer, which was divided into typeⅠ（estrogen-dependent） and typeⅡ（non-estrogen-dependent）; in 1994, Poulsen classified endometrial cancer into adenocarcinoma, serous adenocarcinoma, mucinous adenocarcinoma, clear cell carcinoma, squamous cell carcinoma, mixed carcinoma, and undifferentiated carcinoma by histopathology; in 2013, endometrial carcinoma was divided into four types based on different mutation patterns and copy number by the Cancer Genome Atlas （TCGA）: polymerase epsilon（POLE） mutated, microsatellite instability, copy number-low and copy number-high. The molecular classification has important guiding significance for the precise treatment of patients with different subtypes and prognosis prediction of patients. In this review, we summarize three classifications of endometrial carcinoma, list their advantages and limitations, and highlight the clinical significance of endometrial cancer. The continuous improvement of classification of endometrial cancer will help to understand the heterogeneity in prognosis, guide the choice of treatment strategies, and lay a theoretical foundation for standardized, individualized and humanized treatment in the era of precision medicine.

Key words: Endometrial neoplasms, Carcinoma, Neoplasm staging, Pathological classification, Immunotherapy, Fertility